Inozyme Pharma

📍 Boston, United States🗓 Founded 2016👥 66 employees💰 Last funded Dec 2019
Biotechnology Research🌐 inozyme.com
Website LinkedIn
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
4
Total investors
2
Early stage
2
Mid stage
0
Late stage
2016
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2016–2019 · investors recorded per year
2016220192
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Inozyme Pharma?
Inozyme Pharma has 4 investors on record on gritt.io, including 2 early-stage backers, 2 mid-stage.
When did Inozyme Pharma last raise funding?
The most recent investment in Inozyme Pharma recorded on gritt.io was in December 2019.
When was Inozyme Pharma founded?
Inozyme Pharma was founded in 2016.
What industry is Inozyme Pharma in?
Inozyme Pharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Inozyme Pharma based?
Inozyme Pharma is headquartered in Boston, United States.